CytomX Therapeutics, Inc.·4

Dec 22, 4:12 PM ET

Landau Jeffrey B 4

4 · CytomX Therapeutics, Inc. · Filed Dec 22, 2023

Insider Transaction Report

Form 4
Period: 2023-12-20
Landau Jeffrey B
Chief Business Officer
Transactions
  • Sale

    Common Stock

    2023-12-20$1.38/sh4,077$5,62886,622 total
Holdings
  • Common Stock

    (indirect: By IRA)
    4,500
  • Common Stock

    (indirect: By IRA)
    3,180
Footnotes (2)
  • [F1]The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs previously reported on December 19, 2023.
  • [F2]Includes 52,205 restricted stock units.

Documents

1 file
  • 4
    form4.xmlPrimary